Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ramm Pharma ( (TSE:RAMM) ) has provided an announcement.
RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.
More about Ramm Pharma
RAMM Pharma is a company engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp-based products. It operates a diversified international production and sales platform, with a significant presence in Uruguay where it develops and sells medically registered cannabinoid pharmaceutical products in various Latin American countries. The company also has operations in Europe, particularly in Italy and Poland, and includes subsidiaries like Canapar Corp. and HemPoland.
YTD Price Performance: 0%
Average Trading Volume: 146,334
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$1.79M
See more data about RAMM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue